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ABSTRACT 
 
 
Effect of Pseudoephedrine on 800-Meter Run Times of  
 
NCAA Division I Women Athletes 
 
 
by 
 
 
Caroline Berry, Master of Science 
 
Utah State University, 2011 
 
 
Major Professor: Dr. Dale R. Wagner 
Department: Health, Physical Education and Recreation  
 
 
Pseudoephedrine is an over-the-counter drug commonly used as a decongestant, 
but also thought to have ergogenic effects. The World Anti-Doping Agency (WADA) has 
prohibited large doses (> 150 µg∙ml-1) of pseudoephedrine, while the National College 
Athletic Association (NCAA) does not include it on the banned substance list. The 
purpose of this study was to examine the effect of body weight dosing of 
pseudoephedrine on 800-m run times of NCAA female runners. Fifteen NCAA female 
track runners volunteered to participate in the randomized, double blind, crossover 
design. In trials that were a week apart, participants were given both 2.5 mg∙kg-1 
pseudoephedrine and a placebo. Ninety minutes post-ingestion, participants completed an 
800-m individual time trial on an indoor track. Finishing time was recorded with an 
automated video timing device. Heart rate and anxiety state scores were recorded 
immediately after each trial. Finally, a urine sample was taken from 5 participants about 2 
hr post-ingestion. Placebo and pseudoephedrine running times were compared using a 
 iv 
paired t test. Heart rate and anxiety state scores were also compared using a paired t 
test. Fourteen runners completed both trials and one was an outlier, giving thirteen 
participants used for statistical analysis. Despite being dosed (144 mg ± 17 mg) well 
above normal therapeutic levels, there was no significant difference (p = 0.92) in 800-m 
times between the placebo (2:39.4 ± 9.6) and pseudoephedrine (2:39.4 ± 9.6) trials, in 
post-exercise heart rate (p = 0.635, pseudoephedrine = 177.9 ± 14.5 beats∙min-1, placebo 
= 178.4 ± 18.5 beats∙min-1), or in anxiety state levels (p = 0.650, pseudoephedrine = 38.4 
± 11.6, placebo = 38.1 ± 8.8). A 2.5 mg∙kg-1 dose of pseudoephedrine had no effect on 
800-m run times in NCAA female runners, and did not raise urine levels above 150 
µg∙ml-1. This raises the question as to why pseudoephedrine is a specified prohibited 
substance by WADA. 
(49 pages) 
 
 
 
 
 
 
 
 
 
 
 
 v 
 
PUBLIC ABSTRACT 
 
Effect of Pseudoephedrine on 800 M Run Times of 
NCAA Division I Women Athletes 
 
The consumption of substances to aid with athletic performance has been a controversial 
issue for some time. The World Anti-Doping Agency (WADA) controls what substances 
are considered legal for athletes to use at the professional level, while the National 
College Athletic Association (NCAA) determines which substances are legal for college 
athletes. In 2010 WADA placed the substance pseudoephedrine on the list of banned 
substances if taken in large amounts. The NCAA does not have pseudoephedrine on the 
banned substance list in any amount. Pseudoephedrine is an active ingredient in over-the-
counter medication that is used to treat symptoms of decongestion. It has been reported 
that pseudoephedrine can improve athletic performance through its ability to increase 
heart rate, assist the blood supply in going from the skin to the skeletal muscle.  
 
While the effects of pseudoephedrine could enhance certain aspects of performance, most 
studies done previously have not found any positive results from its use. There is not a lot 
of research done with the use of pseudoephedrine, but the studies done have been varied 
in the types of performance tested. When looking at anaerobic or endurance performance, 
the majority of studies done found no effect from the pseudoephedrine when using the 
normal drug dose. However, two more recent studies done, have shown improvement in 
performance when using amounts higher than the regular dose of the pseudoephedrine 
medications. 
 
The purpose of this study was to investigate the effects of a body weight dosing of 
pseudoephedrine on the performance of NCAA female track runners in an 800-m run. 
Fifteen female track runners from Utah State University participated in the study.  Each 
participant ran the 800 m twice, a week apart, once with a placebo and once with 
pseudoephedrine. The results showed no difference in the 800-m run times when the 
participants took the pseudoephedrine compared to the placebo. The average time with 
pseudoephedrine was 2:39.4, while the average time with the placebo was also 2:39.4. 
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 CHAPTER I 
INTRODUCTION 
 
 
There are many supplements, drugs, and nutrients that claim to enhance athletic 
performance. The World Anti-Doping Agency (WADA) controls which items are banned 
in every sport for professional athletes, and the National College Athletic Association 
(NCAA) controls the list for all college student-athletes (National College Athletic 
Association [NCAA], 2009; World Anti-Doping Agency [WADA], 2009). Each year 
WADA and the NCAA publish a list of banned substances that are illegal performance 
enhancers and can cause harmful side effects (NCAA, 2009; WADA, 2009). Although 
pseudoephedrine has been thought to be a stimulant and an ergogenic aid, it was removed 
from the banned substance list by WADA in 2004 and placed on a monitoring program 
(Hodges, Hancock, Currell, Hamilton, & Jeukendrup, 2006). In 2010 WADA 
reintroduced pseudoephedrine to the banned list in amounts that exceeded 150 µg∙mL-1 in 
a urinary drug test (WADA, 2010). Pseudoephedrine is not currently on the banned 
substance list for the NCAA (NCAA, 2009). A majority of research examining the 
ergogenic effects of pseudoephedrine has shown little to no athletic performance 
improvement resulting in its removal from the NCAA banned list (NCAA, 2009). 
Pseudoephedrine is a sympathomimetic amine that comes from the plant genus 
Ephedra. Sympathomimetic drugs are substances that are known to exert additional 
effects on the actions of the sympathetic nervous system (SNS) by mimicking 
noradrenalin and adrenaline (Hodges, K. et al., 2006). Pseudoephedrine is mainly an 
alpha-adrenergic agonist that is typically used as an over-the-counter decongestant. The 
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adrenergic receptors are in the muscle lining of blood vessels and when activated by 
pseudoephedrine cause the blood vessels to constrict, allowing less fluid to leave them 
and enter the nose, throat, and sinuses (Hodges, A. et al., 2003). This reduces the severity 
of nasal congestion symptoms. Recommended doses of pseudoephedrine are 60 mg-120 
mg, and most research studies have used these amounts.  
This stimulation of the SNS by pseudoephedrine results in many factors that could 
aid in athletic performance including increased blood pressure, increased heart rate, 
increased oxygen consumption in the brain, increased glycogenolysis in the muscle and 
liver, vasoconstriction in the skin, vasodilation in muscle arterioles, and stimulation of 
the central nervous system (CNS) (Chu, Doherty, Parise, Milheiro, & Tarnopolsky, 
2002). The ability of pseudoephedrine to increase heart rate and cardiac contractility, 
combined with the blood supply going from the skin to the skeletal muscle are main 
factors influencing the belief that pseudoephedrine could play a role as an ergogenic aid 
(Hodges, A. et al., 2003; Hodges, K. et al., 2006). The effect of pseudoephedrine on the 
CNS can cause an athlete to have an amphetamine-like reaction and suppress the feelings 
of fatigue, also acting as an aid in athletic performance (Gillies et al., 1996). 
Sympathomimetics have greatly reduced lipid solubility, which greatly reduces their 
effects on the CNS when compared to amphetamines (Swain, Harsha, Baenzinger & 
Saywell, 1997). Most side effects of pseudoephedrine are minor and uncommon; 
although, excessive excitation of the CNS can occasionally be noticed with healthy 
individuals, which creates the slight risk of insomnia, nervousness, and excitability 
(Clemons & Crosby, 1993). For individuals who are sensitive to sympathomimetics, 
pseudoephedrine can increase the irritability of the myocardium and change the rhythm 
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of the ventricles, but research done previously states that, besides increased heart rate, 
no significant cardiovascular changes occurred in healthy subjects (Clemons & Crosby, 
1993). 
Despite the physiological response to pseudoephedrine making it a potential 
ergogenic aid, there has been very little research done that examines the performance 
enhancing ability of pseudoephedrine in athletics. Most previous research has compared 
the effects of pseudoephedrine to a placebo in the body during exercise. The most 
common change exhibited during exercise, when pseudoephedrine has been taken, is an 
increased heart rate. Other physiological factors have not been shown to change 
significantly with pseudoephedrine, compared to a placebo, making a true basis for 
improved performance with pseudoephedrine hard to determine (Chu et al., 2002; Gill, 
Shield, Blazevich, Zhou, & Weatherby, 2000; Hodges, K. et al., 2006; Swain et al., 
1997). 
To date, most studies have found little or no effect on exercise performance with 
the use of pseudoephedrine. When using the recommended dose of 60 mg 
pseudoephedrine, there was no significant measurable ergogenic effect on high intensity 
exercise (Clemons & Crosby, 1993; Hodges, A. et al., 2003). By taking a higher, but still 
recommended, dose of 120 mg pseudoephedrine there was no performance enhancement 
during anaerobic exercise or with high-intensity exercise lasting for about 1 hr (Chu et 
al., 2002; Gillies et al., 1996). Other research notes that by taking pseudoephedrine 
according to the packaging, six times in a 36-hr period, no improvement was gained in 
5000 m time trial times (Chester, Reilly, & Mottram, 2003). When looking at taking a 
larger than recommended dose of 180 mg of pseudoephedrine, Gill et al. (2000) observed 
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that maximal torque in isometric knee extension and peak power in an all-out Wingate 
test were enhanced. A dose based on body weight, 1 mg kg
-1 
or 2 mg kg
-1
 
pseudoephedrine, did not affect VO2 max or time to exhaustion tests significantly (Swain 
et al., 1997). Overall, these results seem to show that at recommended doses 
pseudoephedrine has little to no effect on performance, but higher doses may be effective 
as ergogenic aids.  
Only one study observed a significant improvement in running times when 
pseudoephedrine was taken prior to performance. K. Hodges et al. (2006) concluded that 
2.5 mg kg
-1
 of body weight of pseudoephedrine ingested 90 min before the exercise bout 
improved performance in 1500-m times by a mean of 5.8 s. The K. Hodges et al. study 
used only male athletes, and only examined them at one distance. Given the inconclusive 
evidence regarding the ergogenic effect of pseudoephedrine at higher doses, the purpose 
of the present study was to examine the effect of 2.5 mg kg
-1
 of body weight of 
pseudoephedrine on 800-m times of NCAA division 1 female distance runners to further 
the research done. Based on previous research, females were asked to participate for two 
main reasons. First, females, when compared to males, are suspected to absorb 
sympathomimetic amines more extensively in their gastro-intestinal tract, which may 
make the effects of pseudoephedrine more apparent (Clemons & Crosby, 1993). 
Secondly, according to Hopkins and Hewson (2001) female elite runners are also more 
reliable test subjects than elite men when looking at time trial results. According to the 
research done by K. Hodges et al. (2006), the research hypothesis of this study is that 2.5 
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mg kg
-1
 of body weight of pseudoephedrine will significantly improve athletic 
performance in the 800-m times of female distance runners. 
With every athlete wanting to get an edge on the competition, knowing what truly 
aids in performance would be a significant finding. Also, if a substance does create a 
stimulating effect during an athletic performance, it needs to be regulated by the NCAA 
to make college competitions fair and keep athletes healthy. If there is no stimulating 
effect of a substance, even when administered at higher doses then the prescribed limit, 
WADA needs to look at the reasoning behind the restriction. 
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CHAPTER II 
REVIEW OF LITERATURE 
 
Introduction 
 
Pseudoephedrine is an over-the-counter drug used to treat sinus and cold 
symptoms. Until recently pseudoephedrine had been on the banned substances list for the 
WADA and the NCAA because it was thought to increase athletes’ performance 
capabilities, but it has now been approved for use on the NCAA level of athletics. The 
amount of research that has been done in using pseudoephedrine as an ergogenic aid is 
limited. Some studies have been done, but they are few and do not cover all of the 
options. This literature review will examine: (a) physiological effects of pseudoephedrine 
on the body, (b) the effect of pseudoephedrine on anaerobic and aerobic performance, (c) 
how pseudoephedrine compares to other ergogenic aids, and (d) variability in running 
performance.      
 
Physiological Effects of Pseudoephedrine on the Body 
 
 
The over-the-counter use of pseudoephedrine is to help symptoms of nasal and 
sinus congestion associated with allergies and the common cold. The properties that 
allow pseudoephedrine to deal with these symptoms affect the body physiologically. 
Some physiological effects of pseudoephedrine are respiratory stimulation, bronchial tube 
dilation, and relaxation of gastrointestinal muscles (Hodges, K. et al., 2006). When taking 
pseudoephedrine it functions mostly as a decongestant through indirectly stimulating the 
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alpha-receptors of the nasal mucosa to vasoconstrict, thereby reducing the blood flow to 
mucosa of the nasal cavity (Chu et al., 2002).   
 Pseudoephedrine is a sympathomimetic substance, so it has been assumed that it 
exerts additional effects on the SNS (Chu et al., 2002). Activation of the SNS results in 
increases in diastolic and systolic blood pressure, heart rate, oxygen consumption in the 
brain, glycogenolysis in the muscle and liver, vasoconstriction in the skin, and 
vasodilation in muscle arterioles (Chu et al., 2002; Gill et al., 2000). By increasing the 
heart rate and blood pressure, the cardiac output increases the blood flow to the working 
muscles (Gill et al., 2000). The vasoconstriction of the skin and vasodilation of the 
muscle arterioles also help to shunt more blood to the skeletal muscle. Glycogenolysis in 
the liver and muscles creates more glucose for the body to use during glycolysis. Through 
increased amount of glucose, the body can produce more energy to use during exercise or 
performance (Chu et al., 2002). In the majority of testing, all the proposed benefits of 
pseudoephedrine do not affect the body with a statistical significance, namely blood 
glucose and lactate show no difference (Bright, Sandage, & Fletcher, 1981; Bye, Hill, 
Hughes, & Peck, 1975; Chester et al., 2003; Chu et al., 2002; Gill et al., 2000; Gillies et 
al., 1996; Hodges, A. et al., 2003; Hodges, K. et al., 2006; Swain et al., 1997). Chu et al., 
Gill et al., and Clemons and Crosby (1993) are some of the only studies to find any effect 
of pseudoephedrine on the body; all three studies found a statistically significant 
difference in heart rate with the use of pseudoephedrine. 
It is likely that some effects of pseudoephedrine on the SNS are mediated by 
neurons indirectly stimulating norepinephrine release from SNS neurons (Chu et al., 
2002). Norepinephrine is a substance that works along side adrenaline, providing the 
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body quick bursts of energy in times of stress, also known as the fight or flight response.  
In theory, augmentation of norepinephrine caused by pseudoephedrine should enhance 
athletic performance (Chu et al., 2002). The body’s increased ability to produce energy 
quickly would be beneficial during performance. 
Pseudoephedrine can also have adverse effects on the body. The activation of the 
SNS, which can come from ingesting small amounts of pseudoephedrine, can increase 
sleeplessness, nervousness, excitability, dizziness, and anxiety (Clemons & Crosby, 
1993). When taken in excess amounts, pseudoephedrine can be associated with 
hallucinations, arrhythmias, hypertension, seizures, and tachycardia (Clemons & Crosby, 
1993). These affects have not been reported with any studies done so far. 
 
Effect of Pseudoephedrine on Anaerobic and Aerobic Performance 
 
 
The pill Sudafed, which comes in amounts of 60 mg per pill or 120 mg per pill, is 
the mostly widely used form of pseudoephedrine. The recommended daily dose is 60 mg 
every 4-6 hr, but not exceeding 240 mg in 24 hr. Overall, studies show no  
effect on high-intensity (anaerobic) performance when using the recommended dose of 
pseudoephedrine. 
A. Hodges et al. (2003) and Bell, Jacobs, and Ellerington (2001) used Wingate 
tests, a 30-s maximal sprint on a bike, to test the anaerobic capacity of the body when 
taking pseudoephedrine. The test showed little to no improvement in the performance 
capabilities of the participants who were taking the recommended 60-mg dose of 
pseudoephedrine. The only difference between pseudoephedrine and the control was an 
elevated heart rate that took a longer time to settle. The participants in A. Hodges et al. 
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study ingested the pseudoephedrine and then waited 90 min before completing the 
Wingate test. The participants in Bell and colleagues’ study ingested pseudoephedrine 
and waited only 60 min before performing the Wingate test. The difference in time 
between ingestion and performance did not make a difference in the results as both 
studies showed no improvement. 
Chu et al. (2002) also used a Wingate test to determine the effect of 
pseudoephedrine on anaerobic performance. The results demonstrated that a 120 mg dose 
of pseudoephedrine did not enhance force production, time to fatigue, fatigue index, or 
power output in young men or women (Chu et al., 2002). The participants in the study 
were given pseudoephedrine 2 hr before they were tested, and rested until the test (Chu et 
al., 2002). The higher dose and longer time in between ingestion and test session still 
showed no improvement in performance. One maximal bike test found an improvement 
with the use of pseudoephedrine. Gill et al. (2000) had participants take 180 mg of 
pseudoephedrine 45 min before exercise, and then perform a 1-RM bench press, 70% 1-
RM bench press, isokinetic knee extension, and a 30 s “all-out” cycle test. They reported 
that a dose of 180 mg of pseudoephedrine increased maximum torque in an isometric 
knee extension, and also increased peak power during an all-out cycle test. Gill et al. 
decided a reason for the improvement shown was the higher dose of pseudoephedrine, 
compared to the doses in other studies, see Gillies et al. (1996).  
For aerobic performance benefits, most studies have also found no benefit from 
the use of pseudoephedrine. When participating in a 40-km time trial, well-trained 
cyclists found no improvement when taking a single therapeutic dose of 120 mg of 
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pseudoephedrine 2 hr before the testing (Gillies et al., 1996). The study was only done 
with the recommended dose and no more. 
Chester et al. (2002) did a study using runners during which pseudoephedrine was 
administered according to the manufacturer’s directions for 36 hr prior to the testing. The 
participants’ testing session included a twenty-minute sub-maximal treadmill test 
followed by a 5000-m time trial. The results showed no statistical difference during the 
20 min of perceived exertion; similarly there was no time difference in the 5000 m time 
when the control was compared to multiple doses of pseudoephedrine.  
Other submaximal testing or time to exhaustion trials state that pseudoephedrine 
had no performance enhancing effect. Swain et al. (1997) studied the effects of 1 mg kg
-1
 
and 2 mg kg
-1
 pseudoephedrine on participants during a cycle test to exhaustion, during 
which participants were expected to maintain 80 rpm with increasing workload; when 
they could not keep the pace the test was stopped. The test resulted in no change in time 
to exhaustion for either amounts of pseudoephedrine when compared to a placebo. In a 
submaximal treadmill test using the Bruce protocol, which consists of 3 min stages of 
increasing intensity, a 60 mg dose pseudoephedrine taken 60 min before testing showed 
no improvement in performance (Clemons & Crosby, 1993). Bright et al. (1981) also 
studied the effects of pseudoephedrine compared to a placebo on a timed multi-staged 
treadmill test to 85% of maximal heart rate. Participants took 60 mg or 120 mg of 
pseudoephedrine 60 min before the treadmill test, and were evaluated based on the time it 
took to reach 85% of maximal heart rate. Results showed no changes in length of time to 
maximal heart rate in either dose of pseudoephedrine when compared to the placebo.  
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 In contrast, two studies have shown performance improvement when 
pseudoephedrine has been given in large doses. Pritchard-Peschek, Jenkins, Oscborne, 
and Slater (2010) administered 180 mg of pseudoephedrine to well-trained athletes 60 
min prior to a cycle time trial. Each participant had to complete a set amount of work (7 
J kg
1
 body mass) in the shortest amount of time possible. When compared to a placebo, 
the cycling time trial performance with pseudoephedrine improved by 5.1%. The authors 
concluded the higher dose was responsible for the drastic improvement (Pritchard et al., 
2010). 
K. Hodges et al. (2006) reported that pseudoephedrine helped lower 1500 m times 
in highly trained male runners. Instead of using the recommended dose, the study took 
the body of weight of the participants and used that to determine the amount of 
pseudoephedrine given to each runner. The equation used was 2.5 mg kg
-1
, which on 
average resulted in 180 mg per person (K. Hodges et al., 2006). When taken 90 min 
before the time trial, the pseudoephedrine improved performance times an average of 5.8 
s, or 2.1%. The increased dose of pseudoephedrine was thought to be the main reason 
why performance improved in this study compared to previous pseudoephedrine studies 
(K. Hodges et al., 2006).  
 
Pseudoephedrine in Use with Other Ergogenic Aids 
 
 
There has been some testing to determine if pseudoephedrine is more effective 
when used with other ergogenic aids. Phenylpropanolamine is another over the counter 
decongestant. When used in conjunction with pseudoephedrine, the combination did not 
enhance performance (Chester et al., 2003). In the study, pseudoephedrine was given to 
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distance runners at the same time as the phenylpropanolamine and separately from 
each other before a 20 min sub-maximal test and a 5000 m time trial. Regardless of 
whether the substances were taken alone or together there was no difference in 
performance from the control group (Chester et al., 2003). 
 Swain et al. (1997) also did a study investigating the effects of pseudoephedrine 
and phenylpropanolamine. The participants took either, 1 mg kg
-1
 or 2 mg kg
-1
 
pseudoephedrine, or 0.33 mg kg
-1
 or 0.66 mg kg
-1
 phenylpropanolamine 1 hr prior to a 
cycle test to exhaustion. The cycle test participants were expected to maintain 80 rpm 
with increasing intensities. The test was stopped when they could no longer maintain the 
cadence. The test resulted in no change in time to exhaustion for either supplement 
compared to a placebo.  
 Silk and Weatherby (2005) did a study using pseudoephedrine and caffeine. The 
study tested the isometric strength and time to fatigue in active young adult men when 
taking both 120 mg of pseudoephedrine alone, and 120 mg of pseudoephedrine combined 
with 300 mg of caffeine. When the two substances were combined there was no 
performance enhancements compared to the control. It was thought that the different 
mechanisms or actions of the pseudoephedrine and caffeine negate the individual 
ergogenic effects when the two are combined (Silk & Weatherby, 2005).  
 
800-Meter Running Performance 
 
 
 The reliability of a performance test is important to a study because it can help 
determine the power of the study or the effectiveness of the treatment. Hopkins and 
Hewson (2001) examined the typical variation of runners’ performances from race to 
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race. According to the data found, a standard was set that in distance races shorter than 
12,000 m any change over 0.5% is significant for a top distance runner. The study also 
found that the faster a runner was, the more reliable they were in testing. Elite women 
runners were also found to be more reliable test subjects than elite men runners (Hopkins 
& Hewson, 2001).  
 Hopkins, Hawley, and Burke (1999) did a study where they found that when 
testing elite athletes, the results did not always carry into the field of their competition. 
The results that were obtained in a laboratory or field tests did not always match the 
results that came from competition scenarios with other athletes, but it was more apparent 
in the elite athletes and not as applicable in other groups of runners (Hopkins et al., 
1999). When using sub-elite athletes the results were deemed to be more reliable. 
 The ability to race well during an 800 m race is considered 75% anaerobic (Paish, 
2009). The anaerobic capacity of an athlete is greatly affected by the athlete’s ability to 
utilize anaerobic glycolysis, the creation of glucose for energy in conditions with an 
oxygen deficit (Chu et al., 2002). Pseudoephedrine affects the SNS by increasing blood 
flow to skeletal muscle and increasing glycolysis. Thus, at a race distance of 800 m, 
pseudoephedrine could affect the anaerobic capacity of an athlete. 
 
Summary 
 
 
Pseudoephedrine is a theoretical ergogenic aid that has only been validated as an 
effective performance enhancer in a few studies while the majority of research indicates 
that it has no benefit, so removing it from the NCAA banned substance list may have 
been the right decision. However, the K. Hodges et al. (2006) study showed that 
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pseudoephedrine could have a significant ergogenic effect if given a sufficient dose. 
These contradicting results suggest that more research should be done to determine if 
pseudoephedrine should really be banned. More studies need to be done to decide if the 
higher dose of pseudoephedrine can affect performance in athletics because most studies 
have been done with the recommended doses. Also, most studies have used men as test 
participants, so doing studies with females is also an area that needs more research. This 
study is patterned after the study by K. Hodges et al. In that study, a 1500-m distance was 
used to test the effects of pseudoephedrine. According to the research, distances less than 
12,000 m are more reliable. The present study examined the 800 m to see if results were 
consistent for this distance. The 800-m distance is considered to use mainly anaerobic 
systems in order to complete the race distance. With the affects of pseudoephedrine on 
the SNS, namely increased blood flow to the skeletal muscles and increased glycolysis, 
the 800 m should be a good distance to test pseudoephedrine versus a placebo. 
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    CHAPTER III 
METHODS 
 
Participants 
 
Fifteen female student athletes from the Utah State University Track and Field 
team were recruited to participate in this study. Before testing each participant had an 
initial screening and medical history done by a physician. The valve function and 
consequent rhythm of the subjects was examined aurally. If it was not deemed safe for 
them to participate, they were excluded from the study. Participants who had blood 
pressure > 140/90 mmHg were also not allowed to participate. Each participant also 
signed an informed consent (Appendix A), outlining risks involved, before participating 
in the study. The Institutional Review Board of the University of Utah approved the 
study. The testing was done at the end of an aerobic training period for the athletes; so all 
subjects were assumedly fit.  
 
Procedure 
 
The study had a double blind, crossover design. Each participant completed two 
800-m time trials, one with pseudoephedrine and one with a placebo. Testing took place 
seven days apart to allow for physical recovery and adequate drug wash out. 
Pseudoephedrine has a half-life of 5.2 – 8 hr, making 7 days sufficient for the drug 
clearance (Kuntzman, Tsai, Brand, & Mark, 1971). Each 800-m trial was performed on a 
200-m indoor track at the Nielson Field house on the campus of Utah State University. 
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The indoor track was used in order to eliminate the variability of the weather between 
each testing session.  
The week before the test session each athlete came to the Dale Mildenberg 
Training Room located at Utah State University for pre-assessment purposes. A doctor 
assessed all participants to ensure their health allowed them to participate in the study 
without adverse effects. All Subjects were cleared and then able to sign an informed 
consent and were given instructions for each testing session. Participants were asked to 
abstain from alcohol and caffeinated foods and beverages within 24 hr of testing, and to 
fast for 8 hr prior to testing in order to eliminate the chance of improved performance due 
to what each participant ate. Also, the student athlete was asked to abstain from 
prescription or over-the-counter medications that contain pseudoephedrine (e.g., Sudafed) 
or could react with pseudoephedrine the week prior to and during the week of testing. 
Student athletes were reminded of the time trial testing a week before the test and then 
again the day before the test. The reminder included information on eating and working 
out instructions for the day of the test. 
At the pre assessment the weight was taken for each participant in clothes they 
were required to wear at the testing sessions. Weight was measured to the nearest 1 kg on 
a Seca 700 balance beam scale (Seca 700, Seca Corp., Ontario, CA). The weight of each 
participant was used to determine the amount of pseudoephedrine or placebo given to 
each participant. It was administered in doses of 2.5 mg kg
-1
 of body weight of 
pseudoephedrine or placebo to each athlete. Maltodexetrin was used as the placebo, and 
to mask the trials each substance was placed in a gelatin capsule and administered in the 
same amount of pills for each condition. A member of the research team then placed the 
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capsules in two different envelopes marked A or B, each containing one substance. 
The contents of the envelopes were known only to this member and were recorded later. 
Envelope A contained pseudoephedrine, while envelope B held the placebo. 
Upon arriving at the indoor track having fasted for 8 hr, heart rate was measured 
on all participants by a polar heart rate monitor (T31, Polar Elector Inc., Lake Success, 
NY) in order to determine a baseline number. Weight was measured again in order to 
ensure no drastic weight changes. Each participant then flipped a coin in order to 
determine which capsule would be ingested that day. If the participant landed with a 
heads side up, envelope A was given. If tails side landed up, the participant was given 
envelope B. Along with the pseudoephedrine or placebo each participant was given an 
Ensure (Abbott Nutrition, Columbus, OH) high-energy shake at 7 ml kg
-1
 of body weight.  
Nutrient distribution of the shake is as follows: protein 14%, carbohydrate 64%, and fat 
22%. The shake was given in order to standardize the pretesting nutrition of each 
participant, so the effect of pseudoephedrine would not change according to the diet of 
the participant. Water was available ad libitum to all participants. 
 After ingesting the nutritional shake and the randomly assigned pseudoephedrine or 
placebo, the subjects each rested for 70 min, sitting and doing homework or reading. At 
the end of the rest, each participant completed a warm-up that lasted 20 min. The warm-
up began with a 1600 m self-paced jog, followed by standardized plyometric drills. 
Immediately preceding the 800 m trial, the subject performed 3 x 50-m strides to finish 
the warm up. At 90 min after ingestion of pseudoephedrine or the placebo, the 800 m trial 
was run individually. The subjects were unable to wear watches and were given no 
encouragement during the run. Split times were given at every 200 m in order to simulate 
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a race. The time trial was timed to the nearest .01 second using the Pyro-bright System 
(Flash Timing, Hillsboro, OR) in order to have accurate timing. Pyro-bright uses a scope 
with an internal clock that started when the gun went off. The signal from the scope is 
sent to a VCR, which recorded the finish from a video camcorder, with the time overlaid 
on the screen.  
 Immediately after the trial, recovery heart rate was taken, again with a polar heart 
rate monitor, to assess the effects of pseudoephedrine on heart rate. The participants were 
then asked to complete the Self-Evaluation Questionnaire developed by Spielberger 
(1983) (Appendix B), in order to determine the anxiety state of each participant. The 
Self-Evaluation Questionnaire was chosen because it is a widely used tool to determine 
state anxiety; other tools are compared to it to determine their effectiveness in state 
anxiety levels (Balon, 2005; Houtman & Baker, 1989). The scoring was done based on 
the answer sheet given in the book, the higher the score the higher the anxiety level 
(Spielberger, 1983) (Appendix C).  
 Five participants were also chosen to give a urine sample, to determine how much 
pseudoephedrine was excreted through the urine with the high doses give. Each urine 
sample was taken approximately 2 hr after pseudoephedrine/placebo ingestion, when 
peak plasma levels should occur (Kuntzman et al., 1971). The participants with heaviest, 
lightest, and median weights were chosen as well as two others, whose names were 
drawn out of a hat. After the urine was collected it was stored in a storage closet on 
campus at room temperature according to the directions of the Associated Regional and 
University Pathologists (ARUP). After both trials had occurred, the urine associated with 
envelope A was taken to the Utah State University Health Center and sent to the ARUP 
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lab. A high performance liquid chromatography/tandem mass spectrometry urinalysis 
was performed by ARUP of Salt Lake City. The full sequence of events is shown in order 
in Table 1. Seven days later the same procedure was performed with each participant 
receiving the treatment she did not receive the previous week. Participants were asked to 
give a urine sample after both testing sessions in order to maintain the double blind 
testing procedure. Seven days between trials ensured no treatment contamination and that 
the athlete was fully recovered from the previous trial. Participants were encouraged to 
perform the same tasks and runs the 7 days previous to both trials. Blood lactate was not 
analyzed in this experiment because previous researchers found no change in blood 
lactate from pseudoephedrine (Chester et al., 2003; Chu et al., 2002; Gill et al., 2000; 
Prithchard-Peschek et al., 2010).  
 
Data Analyses 
 An a priori statistical power analysis was performed using GPower 3.1 for sample 
size estimation, based on data from K. Hodges et al. (2006). The effect size (ES) was 1.3, 
extremely large using Cohen's (1988) criteria (K. Hodges et al., 2006). With a one-tailed 
alpha = 0.05 and power = 0.80, the projected sample size for this ES (GPower 3.1) is 
approximately N = 6 for this simplest within group comparison. Thus, our proposed 
sample size of N = 15 should have been more than adequate for the main objective of this 
study. According to the same power analysis, each participant would have needed to 
differ by 3.1 s between the pseudoephedrine and placebo trials in order to achieve 
statistical significance. 
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Table 1 
Timeline of Data Collection 
Procedure Steps Running Time 
1. Participant arrives 00:00 min 
2. Weight check 02:00 min 
3. Treatments Selection 
Flip coin 
-Heads Envelope A 
-Tails Envelope B 
05:00 min 
4. Administration  
-Envelope with capsules 
-Nutrition shake 
10:00 min 
 
5. Rest/ Wait Period 80:00 min 
6. Warm up 
-1600 m self-paced jog 
-plyometric drills 
-3 x 50 m strides 
100:00 min 
7. Time Trial 102:00-103:00 min (90:00 min post 
ingestion of capsules) 
8. Post exercise heart rate recorded 104:00 min 
9. Post exercise anxiety state written test 114:00-124:00 min 
10. Post exercise urine sample 130:00 min (110:00-120:00) min post 
ingestion of capsules) 
11. Cool down Self Selected 
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Paired sample t tests were used to determine if the mean difference in 800-m 
run time was significant between pseudoephedrine and placebo trials, as well as to 
compare mean differences in post-exercise heart rate and anxiety state between trials. 
Statistical significance was set at p < 0.05. Statistical analysis was done using the 
Statistical Package for the Social Sciences (SPSS, version 18.0). 
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   CHAPTER IV 
RESULTS 
 
 
The purpose of this study was to determine if pseudoephedrine acted as an 
ergogenic aid for women NCAA track and field athletes in the 800-m distance. The study 
started with 15 participants. No participants were deemed unable to begin the study for 
medical reasons. Due to injury, one participant was unable to finish the study. Another 
participant ran a 2:46.9 with pseudoephedrine and a 3:00.5 with the placebo, suffering 
from illness on testing day two. With a difference in 800-m times between trials 
exceeding standardized score of 3.29 this participant was considered an outlier 
(Tabachnick & Fidell, 1996). Thus the number of participants used for statistical analysis 
totaled 13 (see Table 2).  Individual subject results are included in Appendix D. 
 
Table 2 
Participants Characteristics (N = 13) 
Variable Mean (SD) Range (min-max) 
Height (cm) 165.9 (10.6) 157.5 – 180.3 
Mass (kg) 57.6 (6.4) 50.0 – 72.0 
Age (years) 19.6 (1.3) 18 - 23 
BMI (kg/m
2
) 20.6 (1.5) 18.5 – 23.2 
Dosage (mg) 144 (17) 130 - 170 
800-m time 
Placebo 
 
2:39.4 (9.6) 
 
2:24.7 – 2:55.1 
800-m time 
Pseudoephedrine 
2:39.4 (9.6) 
 
2:27.5 – 2:55.6 
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Despite being dosed (144 mg pseudoephedrine ± 17 mg) well above normal 
prescribed levels, there was no significant difference (p = 0.92) in 800 m times between 
the placebo (2:39.4 ± 9.6) and pseudoephedrine (2:39.4 ± 9.6) trials. The  
difference between trials for each participant is illustrated in Figure 1. 
 
 
 
 
Figure 1. Time difference between trials (pseudoephedrine - placebo) for each  
     participant. 
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The difference in post-exercise heart rates between the pseudoephedrine (177.9 
± 14.5 beats∙min-1) and placebo (178.4 ± 18.5 beats∙min-1) trials was not significant (p = 
0.635) The mean of heart rates for each trial is illustrated in Figure 2. Also, there were no 
significant differences (p = 0.650) in anxiety state scores between the pseudoephedrine 
(38.4 ± 11.6) and placebo (38.1 ± 8.8) trials (Figure 3). 
 
 
 
 
Figure 2. Post-exercise heart rates (mean ± SE) for 800-m trials. 
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Figure 3. Anxiety state scores (mean ± SE) for 800-m trials. 
 
 
A urine excretion test was also done on five participants. The WADA limit is 150 
micrograms of pseudoephedrine per milliliter of urine. The lab reported the 
pseudoephedrine excretion in nanograms per milliliter. When converted, participant 7 
excreted 3.4 µg ml
-1
, participant 8 excreted 2.7 µg ml
-1
, participant 9 excreted 
.11 µg ml
-1
, participant 11 excreted 7.3 µg ml
-1
, and participant 14 excreted 5.3 µg ml
-1
. 
These are very low numbers according to the doses given. The ARUP Lab, where the test 
was done, was contacted about a possible mistake in numbers and could not identify a 
problem. 
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 Contrary to the hypothesis, the pseudoephedrine did not significantly lower the 
800-m run times of women NCAA track athletes compared to a placebo. Furthermore, 
according to the results pseudoephedrine did not create a statistically significant change 
in heart rate or anxiety states when compared to a placebo during a performance 
situation. 
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    CHAPTER V 
DISCUSSION 
The purpose of this study was to determine the effect of 2.5 mg kg
-1
 of body 
weight of pseudoephedrine on 800 m run time of NCAA division 1 female distance 
runners. The hypothesis that stated pseudoephedrine would significantly improve 800 m 
run times was not supported in the research findings.  
 According to the Track & Field Results Reporting System (TFRRS; 2011) the top 
500 times of NCAA women indoor track athletes were all faster than 2:16. The present 
study’s mean time of 2:39 was slower than the top 500. Althetic.net (2011) reported 
1,000 high school females out of 3510 submitted times ran under a 2:38, the website only 
reported the top 1,000 race times entered. The present study average of 2:39 was faster 
than two thirds of high school female track athletes. This study used NCAA female track 
athletes after an aerobic training period. The training they were doing was for distances 
longer than 800 m, which may have made the times slower then the top 500 times of 
college. The study still can be generalized for above average high school female track 
runners and mediocre NCAA track runners. The NCAA reported that 11,816 female 
athletes participated on an indoor track team in 2010, making an average time hard to 
find because all websites only present the best times available (NCAA, 2011). 
 Pseudoephedrine is thought to have some adverse effects, when taking high 
amounts of it. No participants in the current study reported any problems associated with 
the ingestion of pseudoephedrine. 
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The results of this study were not consistent with those of K. Hodges et al. 
(2006) who found that 2.5 mg kg
-1
 body weight of pseudoephedrine improved elite male 
runner 1500-m times on average of 5.8 s. The present study was modeled after the K. 
Hodges et al. study, but was a shorter distance and different gender of participants. The 
differences in study design were thought to be able to enhance the effects of 
pseudoephedrine even further, but failed to give statistical improvement at all. A possible 
explanation for the differing results is the dosage given to the participants. Both studies 
gave 2.5 mg kg
-1
 body weight of pseudoephedrine, but the larger athletes in the K. 
Hodges et al. study received 180 mg pseudoephedrine on average compared to the 145 
mg pseudoephedrine in the current study. Giving a larger absolute value regardless of 
body mass compared to the regular dose (60-120 mg), may be needed for performance 
enhancement.  
 In a study done by Pritchard-Peschek et al. (2010), using a higher dose of 
pseudoephedrine was also the reason given for improvement in performance. When 
giving 180 mg pseudoephedrine, there was a 5.1% improvement in time during a cycling 
time trial. The effect of the higher dose on the body was the only reason found for 
improvement when compared to other studies (Pritchard-Peschek et al., 2010). 
Gill et al. (2000) also used a 180-mg dose of pseudoephedrine per participant and 
found some increase in peak power during an all-out cycle test. The increased amount of 
pseudoephedrine was the reason for improvement found by Gill et al. when compared to 
other studies, further supporting the evidence that a higher dose could act as an ergogenic 
aid. 
 29 
 The present study does support the findings in many other studies, all of which 
the participants took the therapeutic dose or just barely above it. A. Hodges et al. (2003) 
and Bell et al. (2001) also showed no improvement in Wingate tests when taking only 60 
mg pseudoephedrine. Similar to the present study, Swain et al. (1997) used 1 mg kg
-1
 and 
2 mg kg
-1
 pseudoephedrine and saw no improvement in cycle tests to exhaustion. The 
relative amount per body mass may not be as important as the overall effect of having a 
higher absolute dose compared to what is recommended.  
Heart rate is another variable considered in pseudoephedrine studies. In the 
present study there was no increase in heart rate immediately after completing the time 
trial when taking pseudoephedrine compared to the placebo. These results support a 
majority of previous research, but are contrary to the findings of Bye et al. (1975), Chu et 
al. (2002), Gill et al. (2000), and Clemons and Crosby (1993), which all found increased 
heart rate from pseudoephedrine. This study used NCAA athletes, whereas the other 
studies used participants labeled healthy adults or recreational athletes. The higher fitness 
level of the athletes may affect the magnitude of change pseudoephedrine can have on the 
heart rate of an individual. In K. Hodges et al. study of elite athletes with high fitness 
levels no difference was found in heart rate between the pseudoephedrine and placebo 
trials, even when using an average of 180 mg pseudoephedrine per person. This adds 
support to the theory that higher fitness levels are less affected by pseudoephedrine.   
The present study compared the effect of pseudoephedrine to a placebo on anxiety 
states. No other studies reported looking at anxiety state levels of participants. Despite 
the effect of pseudoephedrine on the CNS there was no difference in anxiety states 
between trials. A higher score signifies a higher anxiety level at the time the test is taken. 
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For each trial, the mean score was 38. The average score for a college female on the 
Self-Evaluation Questionnaire is a 39 (Spielberger, 1983). This suggests that even after 
taking pseudoephedrine, the study participants had an anxiety level comparable to the 
average college-aged female. This may result from the fact that as a NCAA track athlete, 
the participants, are accustomed to the stressors related to race performance. The 
pseudoephedrine was not given in high enough amounts to affect the state of the athletes. 
The lack of increased heart rate shows the lack of effect of pseudoephedrine on the 
physiological systems of the body, which helped the athletes feel the same during each 
trial. With no direct changes in the body, feelings of anxiety would be the same as every 
other race or time trial.  
 The results of the urine test were not as expected. With the amounts of 
pseudoephedrine given, the amount in the urine was expected to be above or near the 
WADA limit of 150 g ml
-1
. The results indicated that the levels were not near this limit; 
in fact, they were very near zero. Based on research done previously WADA stated that 
amounts over 120 mg dose in 12 hr would have a urine excretion rate over the limit 
(WADA, 2009). According to the results of the present study this may not be the case. At 
2 hr after ingestion, pseudoephedrine should be at high levels in the urine (Kuntzman et 
al., 1971). Each participant gave the urine sample near 2 hr after ingestion, so the levels 
in the urine should have been higher. The lab where the urinalysis took place stated that 
each individual metabolizes pseudoephedrine differently and may result in varying times 
of maximum urine excretion. The low concentration of pseudoephedrine in the urine, 
despite the large dose given, could not be explained.  
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According to the results of this study, pseudoephedrine does not need to be on 
the banned list in the amounts listed by WADA. WADA stated that amounts over 120 mg 
dose in 12 hr would have a urine excretion rate over the limit, and is banned (WADA, 
2009). The present study administered an average 144 mg of pseudoephedrine per person, 
which exceeds the amount stated by WADA, with no ergogenic effects exhibited. Based 
on the present study, if an athlete takes pseudoephedrine for a cold in amounts exceeding 
120 mg per 24 hr there will be no performance benefit, but there could be repercussions 
from WADA. The NCAA is right by not putting it on the banned list, because no 
performance benefits were found despite the dosing above therapeutic levels.  
 
Study Limitations 
 
 
 Some limitations should be listed for the current study to assist with further 
research. First, the participants were at the end of an aerobic training period, doing little 
to no anaerobic training. The aerobic training gave the participants fitness, but not in the 
exact area needed during an 800-m race. If the participants had been doing anaerobic 
training there may have been more consistent race times from person to person, creating a 
smaller standard deviation. 
 Another limitation of the study was relying on the honesty of the participants to 
follow the instructions outlined for the study. If participants changed the routine from 
week to week that could have changed results. Also, if participants didn’t follow the 
dietary guidelines the results could have been affected as well.  
 The final limitation was the timing of the urine test. With each person 
metabolizing pseudoephedrine differently, there may be a need to do more than one urine 
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test. If the multiple urine tests could have been analyzed the results of the urinalysis 
could have shown more amounts of pseudoephedrine. 
 
Future Research 
 
 Although the current study had few limitations, there are some recommendations 
that should be considered for future research. One recommendation would be to use 
athletes that are in or finishing an anaerobic training period. Another recommendation 
would be to do multiple urine tests on each participant to better assess if the WADA 
limits are reached. Lastly, if a test of norepinephrine could have been done on the 
participants more information could have been given about the effects of 
pseudoephedrine on the body. Future research done with these recommendations would 
help further the area of research dealing with pseudoephedrine and performance. 
 
Conclusion 
 
The results of this study do not support the hypothesis that stated pseudoephedrine 
would improve the 800-m race times of NCAA track and field female runners. Despite all 
the effects of pseudoephedrine on the CNS and SNS, pseudoephedrine also had no effect 
on heart rate or anxiety states of participants when compared to a placebo. If 
pseudoephedrine has no effect on performance, WADA may want to reconsider the 
inclusion of this over-the-counter drug on their banned substance list in the future.  
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Consent Document 
 
Effect of Pseudoephedrine on 800-m Run Times of NCAA Division-I Women 
Athletes 
 
BACKGROUND 
You are being asked to participate in a research study. It is important for you to 
understand why the research is being done and what will be asked of you before you 
make a decision about participating in this study. Please carefully read this information 
and ask the researcher if there is anything that is not clear or if you want more 
information. 
 
The purpose of this research is to determine if pseudoephedrine, an over-the-counter 
drug and an ingredient commonly found in nasal decongestants, can improve 800-m run 
performance in NCAA female runners. You are being invited to participate in this study 
because you are a female runner on the Utah State University cross-country or track 
team. We anticipate having a total of 15 collegiate runners complete this study. This 
study is being conducted by Dr. Dale Wagner, Assoc. Professor of Exercise Physiology 
in the Health, Physical Education and Recreation Department at Utah State University, 
and Caroline Berry, a master’s student in the same department.  
 
STUDY PROCEDURES 
If you decide to participate in this study you will be asked to come to the Dale 
Mildenberg training room once and the Nelson Fieldhouse indoor track twice. Both 
buildings are on the USU-Logan campus. 
 
1) A week before testing you will be asked to come to the Dale Mildenberg training room 
to have an initial screening done by a physician. The physician will be examining your 
heart rhythm and sounds with a stethoscope and checking your blood pressure. If it is 
not deemed safe for you to participate, you will be excluded from the study and the 
physician will advise you of your medical options. Your weight will also be measured at 
this time. This is needed to determine the amount of pseudoephedrine that you will be 
given.  
 
2) If you are cleared by the physician to participate in the study then you will make an 
appointment to meet at the Nelson Fieldhouse indoor track. You will be asked to follow 
pre-testing guidelines: 
a) Abstain from alcohol and caffeinated foods and beverages for 24 hours before 
testing 
b) Abstain from medication containing pseudoephedrine for 24 hours before 
testing 
 c) Fast 8 hours prior to testing 
 d) Do not exercise prior to testing on test day 
 e) Come to the fieldhouse in the same running attire and shoes each testing 
session 
 
3) 24-48 hours before each test session you will receive an email reminder of your 
appointment and the pre-testing guidelines. 
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4) Please arrive on time for your test sessions. Upon arriving the sequence of the test 
will be as follows: 
a) You will be administered pseudoephedrine or a placebo in the amount of 2.5 
mg per kg of body weight; which one you get will be determined randomly from 
a computer-generated number (odd = pseudoephedrine, even = placebo) 
before you arrive. Pseudoephedrine is an over-the-counter stimulant 
commonly used in nasal decongestants. A placebo is a dummy treatment or 
“fake” pill. Neither you nor the test administrator will know which substance is 
being administered (although the test administrator will be able to find out in 
the event of an emergency).  
b) You will also be given a Nutrament high-energy shake administered at 7 ml 
per kg of body weight.  
 c) Your resting heart rate and blood pressure will be taken. 
 d) You will rest for 70 minutes. (You can read a book, listen to music, take a nap,  
     etc.). 
e) Following the rest period, you will begin a 20-minute warm up that begins with 
a   1600 m self-paced jog, followed by standardized plyometric drills 
(bounding, skipping, etc.), and conclude with 3 x 50 m strides. 
f) Following the warm-up and at 90 minutes after ingestion of the 
pseudoephedrine or the placebo, the 800 m time trial will begin. You will run 
the 800 m as fast as you can. You will receive split times at every 200 m, but 
no other encouragement. 
g) Upon finishing the 800 m, you will cool-down at a self-selected pace and heart 
rate will be taken every minute for five minutes. 
 
5) Seven days later at the same time, these exact steps (#4 a-g) will be followed, except 
that you will receive the treatment (pseudoephedrine or placebo) that you did not receive 
the previous week. Thus, if you complete both test sessions you will receive both the 
pseudoephedrine once and the placebo once. 
 
RISKS 
There are some risks associated with taking pseudoephedrine. In healthy individuals it 
can cause increased sleeplessness, nervousness, excitability, dizziness, and anxiety. 
When taken in excess amounts, pseudoephedrine may be associated with 
hallucinations, fast and irregular heart rates, high blood pressure, and seizures. These 
adverse effects have not been reported in any of the previous similar studies; however, if 
there are problems, a physician will be near the test site, and there is a phone in the 
fieldhouse to call “911” for an emergency. 
 
REPRODUCTIVE RISKS 
This study may involve risks to pregnant women or fetuses that are unknown at this 
time. To be included in the study, you must acknowledge that you are not knowingly 
pregnant. You are permitted to practice any form of birth control during the study. If you 
become pregnant during your participation in this study then you must inform one of the 
researchers immediately, and you will be withdrawn from the study. 
 
BENEFITS 
We cannot promise any benefits to you from your participation in this study. However, if 
you have abnormal heart sounds or abnormal blood pressure this may be identified 
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during the initial health screening by the physician. Also, we hope that both athletes 
and researchers will gain a better understanding of whether or not pseudoephedrine can 
enhance athletic performance from this study. We will provide you with your 800 m time 
for each trial.  
 
CONFIDENTIALITY 
The results of this study may be published, but your identity will not appear. This consent 
form with your signature will be filed in a locked cabinet in the researcher’s office. Only 
Dr. Wagner and Caroline Berry will have access to the data. Computer analysis of the 
data will be numerically coded; your name will not appear on the researchers’ 
computers. Your 800 m time will be revealed only to you; not to your teammates or 
coaches. Because this research involves the use of a drug, the possibility exists that the 
Food and Drug Administration (FDA) may inspect the research records. 
 
PERSON TO CONTACT 
If you have questions, complaints, or concerns about this study, or you think that you 
may be experiencing a medical problem as a result of your participation in this study, 
please contact Dale Wagner, Ph.D. at 435-797-8253 or by email at 
dale.wagner@usu.edu. You can also reach Caroline Berry at 801-694-0335 or by email 
at c.berry@aggiemail.usu.edu. 
 
Institutional Review Board: Contact the Institutional Review Board (IRB) if you have 
questions regarding your rights as a research participant. Also, contact the IRB if you 
have questions, complaints or concerns which you do not feel you can discuss with the 
investigator. The University of Utah IRB may be reached by phone at (801) 581-3655 or 
by e-mail at irb@hsc.utah.edu.   
 
Research Participant Advocate:  You may also contact the Research Participant 
Advocate (RPA) by phone at (801) 581-3803 or by email at 
participant.advocate@hsc.utah.edu.  
 
RESEARCH-RELATED INJURY 
If you are injured from being in this study, medical care is available to you at the 
University of Utah, as it is to all sick or injured people. The University of Utah does not 
have a program to pay you if you are hurt or have other bad results from being in the 
study. The costs for any treatment or hospital care would be charged to you or your 
insurance company (if you have insurance), to the study sponsor or other third party (if 
applicable), to the extent those parties are responsible for paying for medical care you 
receive. Since this is a research study, some health insurance plans may not pay for the 
costs.  
 
The University of Utah is a part of the government. If you are injured in this study, and 
want to sue the University or the doctors, nurses, students, or other people who work for 
the University, special laws may apply. The Utah Governmental Immunity Act is a law 
that controls when a person needs to bring a claim against the government, and limits 
the amount of money a person may recover. See Section 63G -7-101 to -904 of the Utah 
Code. 
 
VOLUNTARY PARTICIPATION 
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Your decision to participate in this study is entirely up to you. If you decide to take 
part, you are still free to withdraw at any time without giving a reason. You just need to 
inform the researchers of your desire to withdraw from the study. There are no 
consequences for declining to participate or deciding to withdraw from this study. Your 
participation decision will not affect your relationship with the coaches or your status on 
the team.  
 
UNFORESEEABLE RISKS 
In addition to the risks listed above, you may experience a previously unknown risk or 
side effect. 
 
RIGHT OF INVESTIGATOR TO WITHDRAW 
The investigator can withdraw you without your approval. Possible reasons for 
withdrawal include you becoming pregnant during the course of the study or the study 
being terminated early because of unforeseen negative effects of the pseudoephedrine. 
 
COSTS AND COMPENSATION TO PARTICIPANTS 
There is no cost to you for participating in this study. You will not be compensated for 
your participation.  
 
NEW INFORMATION 
Sometimes during the course of a research study, new information becomes available 
about the drug being studied. If this happens, the researcher will tell you about it and 
discuss with you whether you want to continue in the study. If necessary, you will be 
asked to sign an updated consent form. 
 
NUMBER OF PARTICIPANTS 
We expect to have 15 female collegiate runners participate in this study. 
 
CONSENT 
By signing this consent form, I confirm that I have read the information in this consent 
form and have had the opportunity to ask questions. I will be given a signed copy of this 
consent form.  I voluntarily agree to take part in this study. 
 
 
________________________ 
Participant’s Name 
 
________________________    ____________ 
Participant’s Signature  Date 
 
________________________ 
Name of Person Obtaining Consent 
 
________________________    ____________ 
Signature of Person Obtaining Consent  Date 
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STUDY RESULTS 
It may take several months after your participation is complete for the researchers to 
analyze the data and create a summary of the results.  If you want, the researchers can 
send you a summary of the study results.  Do want a summary of the results mailed to 
you? __yes   __no. 
If yes, please provide your mailing address below: 
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Appendix B: Self-Evaluation Questionnaire 
 45 
 
 46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix C: Scoring Sheet for Self-Evaluation Questionnaire 
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Appendix D: Raw Data 
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RAW DATA 
 
 
NAME 
A/B 
TT1 
A/B 
TT2 
Weight 
Track 
Event 
800m 
TT1 
800m 
TT2 
HR1 HR2 
1 A B 64 kg 800 2:29.843 2:29.912 182 183 
2 A B 60 kg 800/1500 2:55.622 2:55.110 165 145 
3 A B 52 kg 800 2:27.566 2:24.69 175 180 
4 A B 60 kg 800 2:34.877 2:37.788 200 191 
5 A B 57 kg 400/800 2:53.723 2:54.136 179 187 
6 A B 51 kg 800/1500 2:45.962 2:48.524 172 172 
7 B A 50 kg 800 2:29.201 2:31.271 135 152 
8 A B 58 kg 800 2:43.053 2:37.248 186 205 
9 B A 58 kg 800/1500 2:32.268 2:26.929 180 186 
10 B A 56 kg 800/1500 2:42.075 2:41.658 178 152 
11 B A 51 kg 800/1500 2:45.260 2:43.784 174 185 
12 B A 67 kg 800/1500 2:45.761 2:45.577 194 171 
13 A B 72 kg 800/1500 2:32.946 2:32.853 196 183 
14 A B 56 kg 800 2:46.845 3:00.543 188 192 
15 A N/A 54 kg 800/1500 2:45.282 N/A 209 N/A 
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